Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
出版年份 2022 全文链接
标题
Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
作者
关键词
-
出版物
Frontiers in Immunology
Volume 13, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-04-27
DOI
10.3389/fimmu.2022.869676
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma
- (2022) Lea Scherschinski et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A FBXO7/EYA2-SCFFBXW7 axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells
- (2022) Jia Z. Shen et al. MOLECULAR CELL
- Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
- (2022) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hallmarks of Cancer: New Dimensions
- (2022) Douglas Hanahan Cancer Discovery
- Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade
- (2021) Julia Boshuizen et al. CANCER RESEARCH
- A phase II study of sitravatinib (Sitra) in combination with nivolumab (Nivo) in patients (Pts) undergoing nephrectomy for locally-advanced clear cell renal cell carcinoma (accRCC).
- (2021) Jose A. Karam et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- TAM Receptor Inhibition–Implications for Cancer and the Immune System
- (2021) Pia Aehnlich et al. Cancers
- MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
- (2021) Chao-Ju Chen et al. Pharmaceuticals
- Cabozantinib: An Evolving Therapy for Hepatocellular Carcinoma
- (2021) Anthony B. El-Khoueiry et al. CANCER TREATMENT REVIEWS
- Therapeutic Targeting of the Tumor Microenvironment
- (2021) Leire Bejarano et al. Cancer Discovery
- The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications
- (2021) Martha Wium et al. Cancers
- Association of AXL and PD-L1 expression with clinical outcomes in patients with advanced renal cell carcinoma treated with PD-1 blockade
- (2021) Stéphane Terry et al. CLINICAL CANCER RESEARCH
- Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer
- (2021) Mai Tanaka et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.
- (2021) Chung-Han Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels
- (2021) Marie-Anne Goyette et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- AXL Overexpression in Tumor-Derived Endothelial Cells Promotes Vessel Metastasis in Patients With Hepatocellular Carcinoma
- (2021) Zong-Tao Chai et al. Frontiers in Oncology
- VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
- (2021) R.K. Kelley et al. ANNALS OF ONCOLOGY
- Landscape of prognostic signatures and immunogenomics of the AXL/GAS6 axis in renal cell carcinoma
- (2021) Kyohei Hakozaki et al. BRITISH JOURNAL OF CANCER
- Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
- (2021) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study
- (2021) Marc Oliva et al. Journal for ImmunoTherapy of Cancer
- Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis
- (2021) Neus Martínez-Bosch et al. EBioMedicine
- AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew
- (2021) Almira Auyez et al. Cancers
- Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
- (2021) Dan Yan et al. Cancers
- SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models
- (2021) Chun‐Bong Synn et al. Clinical & Translational Immunology
- ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small lung cancer
- (2020) Naoko Okura et al. CLINICAL CANCER RESEARCH
- Tumor Immunology and Tumor Evolution: Intertwined Histories
- (2020) Jérôme Galon et al. IMMUNITY
- A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk.
- (2020) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells
- (2020) Maria L. Lotsberg et al. Journal of Thoracic Oncology
- Engineered IL-7 Receptor Enhances the Therapeutic Effect of AXL-CAR-T Cells on Triple-Negative Breast Cancer
- (2020) Zhenhui Zhao et al. Biomed Research International
- Blockade of Stromal Gas6 Alters Cancer Cell Plasticity, Activates NK Cells, and Inhibits Pancreatic Cancer Metastasis
- (2020) Lucy Ireland et al. Frontiers in Immunology
- AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells
- (2020) Olivier Zajac et al. Cells
- Leukemogenic Chromatin Alterations Promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL Signaling Axis
- (2020) Jiazhen Wang et al. Cell Stem Cell
- Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma
- (2020) Cheong A. Bae et al. Gastric Cancer
- PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).
- (2020) Tian Zhang et al. JOURNAL OF CLINICAL ONCOLOGY
- A conserved dendritic-cell regulatory program limits antitumour immunity
- (2020) Barbara Maier et al. NATURE
- Guidelines and definitions for research on epithelial–mesenchymal transition
- (2020) Jing Yang et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
- (2020) Jenny H. Lee et al. Nature Communications
- Cytoplasmic Expression of AXL Is Associated With High Risk of Postoperative Relapse of Conventional Renal Cell Carcinoma
- (2020) LEHEL PETERFI et al. ANTICANCER RESEARCH
- Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment
- (2020) Mai Tanaka et al. Cancers
- Galectin-3 Stimulates Tyro3 Receptor Tyrosine Kinase and Erk Signalling, Cell Survival and Migration in Human Cancer Cells
- (2020) Nour Al Kafri et al. Biomolecules
- The actin modulator hMENA regulates GAS 6‐ AXL axis and pro‐tumor cancer/stromal cell cooperation
- (2020) Roberta Melchionna et al. EMBO REPORTS
- Targeting the HIF2–VEGF axis in renal cell carcinoma
- (2020) Toni K. Choueiri et al. NATURE MEDICINE
- The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview
- (2020) Niels Schaft Cancers
- Axl and Mertk receptors cooperate to promote breast cancer progression by combined oncogenic signaling and evasion of host anti-tumor immunity
- (2020) Viralkumar Davra et al. CANCER RESEARCH
- TAM kinase inhibition and immune checkpoint blockade– a winning combination in cancer treatment?
- (2020) Pavlos Msaouel et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity
- (2020) Jonathan Rios-Doria et al. Frontiers in Oncology
- TP-0903 is active in models of drug-resistant acute myeloid leukemia
- (2020) Jae Yoon Jeon et al. JCI Insight
- AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
- (2019) Hirokazu Taniguchi et al. Nature Communications
- Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl
- (2019) Juliano D. Paccez et al. Oncogenesis
- Neoantigen-directed immune escape in lung cancer evolution
- (2019) Rachel Rosenthal et al. NATURE
- Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas
- (2019) Yoko Tsukita et al. Molecular Cancer
- Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5- and hypoxia- dependent up-regulation of AXL
- (2019) Pierre-Yves Dumas et al. HAEMATOLOGICA
- Cross-talk between receptor tyrosine kinases AXL and ERBB3 regulates invadopodia formation in melanoma cells
- (2019) Or-Yam Revach et al. CANCER RESEARCH
- Pan-TAM tyrosine kinase inhibitor BMS-777607 enhances anti-PD-1 mAb efficacy in a murine model of triple-negative breast cancer
- (2019) Canan Kasikara et al. CANCER RESEARCH
- Immuno-Oncological Efficacy of RXDX-106, a Novel Small Molecule Inhibitor of the TAM (TYRO3, AXL, MER) Family of Kinases
- (2019) Yumi Yokoyama et al. CANCER RESEARCH
- Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment
- (2019) Kayla V. Myers et al. Molecular Cancer
- Axl and autophagy LC3 expression in tumors is strongly associated with clinical prognosis of hepatocellular carcinoma patients after curative resection
- (2019) Chia‐Chang Hsu et al. Cancer Medicine
- P-238Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
- (2019) L Rimassa et al. ANNALS OF ONCOLOGY
- The novel lnc RNA CALIC upregulates AXL to promote colon cancer metastasis
- (2019) Yoshihiro Kawasaki et al. EMBO REPORTS
- AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer
- (2019) Francesca Collina et al. Cancers
- Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR‐mutated non–small cell lung cancer
- (2019) Yoshikane Nonagase et al. Thoracic Cancer
- AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
- (2019) Stéphane Terry et al. Cancer Immunology Research
- TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti–PD-1 Therapy in Melanoma
- (2019) Alisha Holtzhausen et al. Cancer Immunology Research
- Target‐Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐Informed Dose Selection for the First‐in‐Human Study of AVB‐S6‐500
- (2019) Laura Bonifacio et al. CTS-Clinical and Translational Science
- AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
- (2019) Chenjing Zhu et al. Molecular Cancer
- Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma
- (2019) de Miguel-Pérez et al. Cancers
- AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma
- (2019) Siyang Yan et al. Cancers
- Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
- (2019) Pei-Wen Yang et al. Frontiers in Oncology
- Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
- (2019) Paulo Bergerot et al. MOLECULAR CANCER THERAPEUTICS
- IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma
- (2019) Jason A. Carter et al. NATURE MEDICINE
- Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma
- (2018) Hirokazu Sadahiro et al. CANCER RESEARCH
- A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers
- (2018) Jing Wei et al. CELLULAR IMMUNOLOGY
- The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer
- (2018) Jane Antony et al. EMBO REPORTS
- TP-0903 inhibits neuroblastoma cell growth and enhances the sensitivity to conventional chemotherapy
- (2018) Sanja Aveic et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers
- (2018) Aflah Roohullah et al. INVESTIGATIONAL NEW DRUGS
- Targeting Gas6/TAM in cancer cells and tumor microenvironment
- (2018) Guiling Wu et al. Molecular Cancer
- Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
- (2018) Julia Boshuizen et al. NATURE MEDICINE
- Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib
- (2018) Luís Eduardo Zucca et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial–mesenchymal transition is critical in conquering ALK-positive lung cancer
- (2018) Shinji Nakamichi et al. Oncotarget
- The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
- (2018) Marie-Anne Goyette et al. Cell Reports
- Abstract 5754: Hypoxia-induced tumor plasticity and immune resistance involves an alteration of target recognition by a mechanism involving TGF-beta signaling
- (2018) Stephane Terry et al. CANCER RESEARCH
- HGF-induced formation of the MET–AXL–ELMO2–DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion
- (2018) Wenjing Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents
- (2018) Nellie K McDaniel et al. MOLECULAR CANCER THERAPEUTICS
- The Hippo Pathway: Biology and Pathophysiology
- (2018) Shenghong Ma et al. Annual Review of Biochemistry
- Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation
- (2018) Junsong Zhou et al. Cell Communication and Signaling
- Dynamics of Axl Receptor Shedding in Hepatocellular Carcinoma and Its Implication for Theranostics
- (2018) Elisa Holstein et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer
- (2018) Haley D. Axelrod et al. MOLECULAR CANCER RESEARCH
- Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer
- (2018) Jeanne M. Quinn et al. MOLECULAR CANCER THERAPEUTICS
- Mesenchymal–epithelial transition in development and reprogramming
- (2018) Duanqing Pei et al. NATURE CELL BIOLOGY
- New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
- (2018) Anushka Dongre et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Stromal Gas6 promotes the progression of premalignant mammary cells
- (2018) Angelica M. Gomes et al. ONCOGENE
- The Emerging Role of TYRO3 as a Therapeutic Target in Cancer
- (2018) Sherri Smart et al. Cancers
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression
- (2017) Canan Kasikara et al. MOLECULAR CANCER RESEARCH
- New insights into the role of EMT in tumor immune escape
- (2017) Stéphane Terry et al. Molecular Oncology
- Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
- (2017) Sydney M. Shaffer et al. NATURE
- Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
- (2017) Teresa Davoli et al. SCIENCE
- Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
- (2017) Marie Schoumacher et al. Current Oncology Reports
- Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models
- (2017) Zhiqiang Guo et al. Oncotarget
- MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines
- (2017) Jung Eun Kim et al. Oncotarget
- Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy
- (2017) Ryu Kanzaki et al. Scientific Reports
- Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models
- (2017) Pinar Kanlikilicer et al. Molecular Therapy-Nucleic Acids
- Requirement of Gamma-Carboxyglutamic Acid Modification and Phosphatidylserine Binding for the Activation of Tyro3, Axl, and Mertk Receptors by Growth Arrest-Specific 6
- (2017) Ke Geng et al. Frontiers in Immunology
- Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma
- (2016) Christina L. Roland et al. ANNALS OF SURGICAL ONCOLOGY
- In Vivo Visualization and Characterization of Epithelial–Mesenchymal Transition in Breast Tumors
- (2016) Zhen Zhao et al. CANCER RESEARCH
- EMT: 2016
- (2016) M. Angela Nieto et al. CELL
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
- (2016) Cristina Corno et al. CURRENT MEDICINAL CHEMISTRY
- Sunitinib activates Axl signaling in renal cell cancer
- (2016) Johannes C. van der Mijn et al. INTERNATIONAL JOURNAL OF CANCER
- AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers
- (2016) Kavitha Balaji et al. MOLECULAR CANCER RESEARCH
- Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer
- (2016) Hawa Nalwoga et al. PLoS One
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
- (2016) I. Tirosh et al. SCIENCE
- The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
- (2016) J. Antony et al. Science Signaling
- Reprogramming the immunological microenvironment through radiation and targeting Axl
- (2016) Todd A. Aguilera et al. Nature Communications
- ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types
- (2016) Waltraut Lehmann et al. Nature Communications
- Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
- (2016) M. A. Miller et al. Cancer Discovery
- AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer
- (2016) Laura M. Divine et al. Oncotarget
- The multifaceted role of autophagy in tumor evasion from immune surveillance
- (2016) Bassam Janji et al. Oncotarget
- The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
- (2016) J. Antony et al. Science Signaling
- Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells
- (2016) M Vouri et al. Oncogenesis
- The Receptor Tyrosine Kinase AXL in Cancer Progression
- (2016) Erinn Rankin et al. Cancers
- Axl Expression Stratifies Patients with Poor Prognosis after Hepatectomy for Hepatocellular Carcinoma
- (2016) Jian Liu et al. PLoS One
- TAM Receptor Signaling in Immune Homeostasis
- (2015) Carla V. Rothlin et al. Annual Review of Immunology
- Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma
- (2015) H Yu et al. BRITISH JOURNAL OF CANCER
- AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
- (2015) Moshe Elkabets et al. CANCER CELL
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors
- (2015) S. Sinha et al. CLINICAL CANCER RESEARCH
- AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
- (2015) T. M. Brand et al. CLINICAL CANCER RESEARCH
- Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma
- (2015) Patrick Reichl et al. HEPATOLOGY
- AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
- (2015) Samuel H. Myers et al. JOURNAL OF MEDICINAL CHEMISTRY
- TGF-β and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells
- (2015) Xiao-Hui Chen et al. MOLECULAR IMMUNOLOGY
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies
- (2015) Dass S. Vinay et al. SEMINARS IN CANCER BIOLOGY
- Insights into the roles of hnRNP A2/B1 and AXL in non-small cell lung cancer
- (2015) XIAO-HAN QU et al. Oncology Letters
- Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways
- (2015) Xinyan Wu et al. Oncotarget
- Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
- (2015) Katia Rea et al. Oncotarget
- Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
- (2015) Parag P. Patwardhan et al. Oncotarget
- Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells
- (2015) Maeva Dufies et al. Oncotarget
- The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma
- (2015) Emmy D.G. Fleuren et al. Oncotarget
- Axl as a mediator of cellular growth and survival
- (2015) Haley Axelrod et al. Oncotarget
- GAS6/AXL Axis Regulates Prostate Cancer Invasion, Proliferation, and Survival in the Bone Marrow Niche
- (2015) Yusuke Shiozawa et al. NEOPLASIA
- Identification and Functional Characterization of pVHL-Dependent Cell Surface Proteins in Renal Cell Carcinoma
- (2015) Gunther Boysen et al. NEOPLASIA
- TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis
- (2014) J. H. M. van der Meer et al. BLOOD
- Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial–mesenchymal transition
- (2014) Steven H Lin et al. BMC GENOMICS
- Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway
- (2014) Maolan Li et al. CANCER LETTERS
- AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
- (2014) C. Wilson et al. CANCER RESEARCH
- AXL Mediates Resistance to Cetuximab Therapy
- (2014) T. M. Brand et al. CANCER RESEARCH
- Receptor Tyrosine Kinases, TYRO3, AXL, and MER, Demonstrate Distinct Patterns and Complex Regulation of Ligand-induced Activation
- (2014) Wen-I Tsou et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo
- (2014) Manikandan Subramanian et al. JOURNAL OF CLINICAL INVESTIGATION
- UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor
- (2014) Weihe Zhang et al. JOURNAL OF MEDICINAL CHEMISTRY
- The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
- (2014) Magdalena Paolino et al. NATURE
- An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis
- (2014) Mihalis S Kariolis et al. Nature Chemical Biology
- Tackling the cancer stem cells — what challenges do they pose?
- (2014) Diwakar R. Pattabiraman et al. NATURE REVIEWS DRUG DISCOVERY
- Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
- (2014) Erinn B. Rankin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer
- (2014) Y Wang et al. Cell Death & Disease
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
- (2014) Judith Müller et al. Nature Communications
- A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
- (2014) D. J. Konieczkowski et al. Cancer Discovery
- Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma
- (2013) Pu-xiang Chen et al. Annals of Diagnostic Pathology
- Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients
- (2013) Ju Han et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
- (2013) I. Ben-Batalla et al. BLOOD
- The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma
- (2013) D J Pinato et al. BRITISH JOURNAL OF CANCER
- Localized and metastatic myxoid/round cell liposarcoma
- (2013) Aviad Hoffman et al. CANCER
- AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer
- (2013) P. D. Dunne et al. CLINICAL CANCER RESEARCH
- The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications
- (2013) Juliano D. Paccez et al. INTERNATIONAL JOURNAL OF CANCER
- Genetics and biomarkers in personalisation of lung cancer treatment
- (2013) Rafael Rosell et al. LANCET
- Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
- (2013) Keith M. Giles et al. MOLECULAR CANCER THERAPEUTICS
- Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation
- (2013) Hyeong Ryul Kim et al. Molecular Oncology
- The epigenetics of epithelial-mesenchymal plasticity in cancer
- (2013) Wai Leong Tam et al. NATURE MEDICINE
- AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells
- (2013) M K Asiedu et al. ONCOGENE
- The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells
- (2013) A. S. Meyer et al. Science Signaling
- Higher Expression of Receptor Tyrosine Kinase Axl, and Differential Expression of its Ligand, Gas6, Predict Poor Survival in Lung Adenocarcinoma Patients
- (2012) Masashi Ishikawa et al. ANNALS OF SURGICAL ONCOLOGY
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
- (2012) L. A. Byers et al. CLINICAL CANCER RESEARCH
- Hypoxia Stabilizes GAS6/Axl Signaling in Metastatic Prostate Cancer
- (2012) Anjali Mishra et al. MOLECULAR CANCER RESEARCH
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors
- (2012) S Gusenbauer et al. ONCOGENE
- Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase
- (2012) Martina Ott et al. PLoS One
- Axl Is a Prognostic Marker in Oral Squamous Cell Carcinoma
- (2011) Chien-Hsing Lee et al. ANNALS OF SURGICAL ONCOLOGY
- Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer
- (2011) Chen-Yun Yeh et al. BMC CANCER
- The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma
- (2011) Alvarez Hector et al. CANCER BIOLOGY & THERAPY
- Loss of the receptor tyrosine kinase Axl leads to enhanced inflammation in the CNS and delayed removal of myelin debris during Experimental Autoimmune Encephalomyelitis
- (2011) Jason G Weinger et al. Journal of Neuroinflammation
- Genome-wide Characterization ofmiR-34aInduced Changes in Protein and mRNA Expression by a Combined Pulsed SILAC and Microarray Analysis
- (2011) Markus Kaller et al. MOLECULAR & CELLULAR PROTEOMICS
- Targeting Axl and Mer Kinases in Cancer
- (2011) A. Verma et al. MOLECULAR CANCER THERAPEUTICS
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer
- (2011) G Mudduluru et al. ONCOGENE
- Design, Synthesis, and Biological Evaluation of a Series of Novel AXL Kinase Inhibitors
- (2011) Alexis Mollard et al. ACS Medicinal Chemistry Letters
- PMA up-regulates the transcription of Axl by AP-1 transcription factor binding to TRE sequences via the MAPK cascade in leukaemia cells
- (2010) Giridhar Mudduluru et al. BIOLOGY OF THE CELL
- Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma
- (2010) Xianzhou Song et al. CANCER
- The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target
- (2010) Jan-Bart M. Koorstra et al. CANCER BIOLOGY & THERAPY
- R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer
- (2010) S. J. Holland et al. CANCER RESEARCH
- Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis
- (2010) Nora B Caberoy et al. EMBO JOURNAL
- AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma
- (2010) M Z Xu et al. ONCOGENE
- An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies
- (2010) X Ye et al. ONCOGENE
- Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6
- (2009) S. Loges et al. BLOOD
- Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
- (2009) L. Liu et al. CANCER RESEARCH
- Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival
- (2009) A. Gustafsson et al. CLINICAL CANCER RESEARCH
- Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival
- (2009) C. Gjerdrum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development
- (2008) I.-K. Park et al. BLOOD
- Axl and Growth Arrest Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme
- (2008) M. Hutterer et al. CLINICAL CANCER RESEARCH
- Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1
- (2008) K-Y Tai et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started